Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-Producing recombinant vaccinia viruses

Annals of Surgical Oncology

Volumn 3, Issue 1, 1996, Pages 15-23

  Peplinski, Gary R ^a   Tsung, Kangla ^a   Meko, Jennifer B ^a   Norton, Jeffrey A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Gene therapy; Neoplasm; Vaccinia virus

Indexed keywords

CYTOKINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; C3H MOUSE; CELL CULTURE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETICS; METABOLISM; MOUSE; PASSIVE IMMUNIZATION; PROMOTER REGION; VACCINIA VIRUS; VIRUS GENOME;

ANIMALS; CYTOKINES; FEMALE; GENE EXPRESSION; GENETIC VECTORS; GENOME, VIRAL; IMMUNIZATION, PASSIVE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; VACCINIA VIRUS;

EID: 0029685742     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02409046     Document Type: Article

References (29)

1. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993;261:209-11.
2. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992;339:715-21.
3. Russell SJ. Lymphokine gene therapy for cancer. Immunol Today 1990;11:196-200.
4. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-6.
5. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991;88:8039-43.
6. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1994;1:51-64.
7. Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994; 54:3325-8.
8. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 1983; 25:21-8.
9. Davison AJ, Moss B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucl Acids Res 1990; 18:4285-6.
10. Davison AJ, Moss B. Structure of vaccinia virus early promoters. J Mol Biol 1989;210:749-69.
11. Baldick CJ, Moss B. Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes. J Virol 1993;67:3515-27.
12. Davison AJ, Moss B. Structure of vaccinia virus late promoters. J Mol Biol 1989;210:771-84.
13. Moss B. Regulation of vaccinia virus transcription. Ann Rev Biochem 1990;59:661-88.
14. Earl PL, Moss B. Protein expression IV: expression of proteins in mammalian cells using vaccinia. In: Ausubel FM, Brent R, Kingston RE, et al. Current protocols in molecular biology. New York: Greene Publishing Associates and Wiley-Interscience, 1991:16.15.1-16.18.10.
15. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-lβ. Ann Surg Oncol 1995;2:151-9.
16. Smith GL, Mackett M. The design, construction and use of vaccinia virus recombinants. In: Binns MM, Smith GL, eds. Recombinant poxviruses. Boca Raton, FL: CRC Press, 1992:81-122.
17. Mackett M, Smith GL, Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 1984;49:857-64.
18. Chakrabarti S, Brechling K, Moss B. Vaccinia virus expression vector: coexpression of b-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 1985; 5:3403-9.
19. Falkner FG, Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 1992;62:1849-54.
20. Pardoll DM. Cancer vaccines. Immunol Today 1993; 14: 310-6.
21. Brochier B, Kieny MP, Costy F, et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991;354:520-2.
22. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984;311:750-2.
23. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985;315:301-5.
24. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5.
25. + T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
26. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 countereceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1993;71:1093-102.
27. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
28. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173:889-97.
29. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993:90:3539-43.